Drugs / Bowman-Birk inhibitor concentrate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00679094 | Jun 2007 → Dec 2009 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00287833 | Jan 2006 → Apr 2007 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00330382 | Jan 1999 → Jul 2010 | lip and oral cavity carcinoma, oral mucosa leukoplakia, oropharyngeal carcinoma, tongue cancer | National Cancer Institute (NCI) | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bowman-Birk inhibitor concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00287833 ↗ |
| Known as | BBIC | “single-dose Bowman-Birk Inhibitor Concentrate (BBIC)” NCT00679094 ↗ |
| Route | Oral | “Given orally” NCT00287833 ↗ |